The bill is 45,000 euros and two lost trials

When a traffic light stops working there are road rules that we must follow until it is repaired. The worst thing is when this repair takes several days, causing chaos in traffic. That was what happened in 2023 in Valencia, and the dispute between the Superior Court of Justice of the Valencian Community (TSJCV) and the maintenance company remained unresolved until a few days ago. What happened. For five days in November 2023, the pedestrian traffic light located on Doctor Manuel Candela Avenue with Santos Justo y Pastor Street showed the red light and the green light at the same time. According to they count From El Motor, the first alert was registered on November 14 at 6:45 in the morning. Four days later, a municipal inspection confirmed that the problem remained unresolved. Why did it take so long? The origin of the failure, according to the Valencia City Council, was that the company that had to take charge replaced the burned out halogen lamps. for other LED types with E27 socket. Municipal services described them as “glaringly unsuitable for traffic light networks.” The problem, furthermore, was not only the type of bulb that was used, but the technical procedure they followed to install them. A procedure that municipal reports described as “technically inappropriate.” blegal attack. The City Council imposed a penalty of 45,000 euros on Electronic Trafic SA, the company awarded the contract. The company appealed, arguing that it had resolved two different breakdowns, both in less than two hours, and that the council had “deliberately” confused the terms breakdown and incident, which would entail different economic implications depending on the contract. He also alleged “animosity” from the head of the Mobility Service towards the company. The courts did not see it that way. What the judges said. The TSJCV confirmed the sanction on February 26, supporting the City Council’s thesis. The sentence highlights “the seriousness of the behavior followed by the contractor”, which left the incident unresolved for more than four days at an intersection where there is special traffic. The court highlighted that the municipal reports were “highly precise and exhaustive” and that the company did not provide sufficient technical evidence to refute them. According to point The Motor, in addition to the 45,000 euros, the company must pay 2,500 euros in procedural costs. What this sentence implies. The issue here is that the company notified of the problem but the traffic light continued not to work correctly during those days. Therefore, the city council insist in which the responsibility falls on the company, from notification to solution. The failure being a traffic light, a critical road safety device, all the more so the urgency of finding a solution. More and more cities are outsourcing intelligent traffic management to private companies, and the ruling certainly sets a precedent. What happens now? The crossing operates normally. The ruling still allows for an appeal, although the fact that two different courts have endorsed the city council’s position means that the company has little room for maneuver. Cover image | Georgi Zvezdov In Xataka | We already have the VAT discount at the pump: now the battle begins to prevent gas stations from absorbing it

US grants almost $600 million to Moderna to “accelerate” bird flu vaccine trials

The United States government has allocated a significant investment of almost $600 million to the biopharmaceutical company Moderna to accelerate the development of vaccines based on messenger RNA (mRNA) against avian flu, with special emphasis on flu strains that could become a pandemic threat. This financial support is part of the Department of Health and Human Services’ (HHS) ongoing efforts to anticipate and mitigate the risk of future public health crises, such as those caused by highly contagious and dangerous influenza viruses. Since 2023, Moderna has been working closely with the Biomedical Advanced Research and Development Authority (BARDA), an HHS entity, to develop mRNA vaccines. that can be used in the event that new strains of influenza emerge with the potential to become pandemics. This effort includes not only the research and development of vaccines against the H5N1 strain of bird flu, but also against other variants that could represent a danger to global health. In 2023, Moderna had already received $176 million as part of this initiative, and with the recent allocation of funds, the company will be able to accelerate its work and move more quickly toward creating an effective vaccine. One of Moderna’s key advances in this project is its mRNA-1018 vaccine, which is designed to combat the H5 and H7 bird flu viruses. This vaccine has demonstrated “positive preliminary data” in Phase 1 and 2 clinical trials, leading to optimism about its effectiveness in combating these dangerous strains. With additional funding provided by the US government, Moderna is in the preparation phase of launching a Phase 3 study of this vaccine, a crucial step towards its possible distribution in the event of a massive outbreak of bird flu. Face future threats The company intends to share findings from these trials at an upcoming medical conference, which could offer more insight into the vaccine’s potential to address future viral threats. The recent HHS funding will also allow Moderna to accelerate research and development of a vaccine against the H7N9 strain of bird flu, another variant that has concerned health authorities due to its ability to infect humans. Public health officials have noted that the speed with which new flu strains emerge and spread necessitates an innovative and flexible approach to vaccine development. In this regard, the US government’s financial support is designed to expand Moderna’s clinical trials, enabling the evaluation of multiple vaccines and increasing the database supporting the use of mRNA technology in these contexts. In addition to ongoing work with the H5N1 and H7N9 strains, HHS has expressed interest in having Moderna design up to four new vaccines against different flu strains that can be evaluated in Phase 1 studies. The goal of this initiative is to generate clinical data that supports the accelerated development of mRNA vaccines, that would be essential to contain future outbreaks of avian flu or any other influenza strain with pandemic potential. As flu viruses continue to mutate, the ability to quickly adapt to new variants will be key to preventing a global pandemic. Keep reading:

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.